• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型抗菌剂ABT-719及相关2-吡啶酮对实验性细菌感染的疗效。

Efficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections.

作者信息

Alder J, Clement J, Meulbroek J, Shipkowitz N, Mitten M, Jarvis K, Oleksijew A, Hutch T, Paige L, Flamm B

机构信息

Anti-Infective Research Division, Abbott Laboratories, Abbott Park, Illinois, USA.

出版信息

Antimicrob Agents Chemother. 1995 Apr;39(4):971-5. doi: 10.1128/AAC.39.4.971.

DOI:10.1128/AAC.39.4.971
PMID:7786005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC162663/
Abstract

The 2-pyridones are a new class of broad-spectrum orally bioavailable antibacterial agents. These compounds are potent bacterial DNA gyrase inhibitors which differ from fluoroquinolones by placement of the nitrogen atom in the ring juncture. ABT-719 is an S isomer and a representative 2-pyridone. ABT-719 administered orally or subcutaneously was 4- to 10-fold more effective than ciprofloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes infections in normal mice. ABT-719 was equivalent in efficacy to ciprofloxacin for treatment of gram-negative bacterial infections caused by Pseudomonas aeruginosa or Escherichia coli. The racemate and R forms of ABT-719 produced similar results against gram-positive and gram-negative bacterial infections. The 50% effective doses of ABT-719 were at least threefold lower than those of ciprofloxacin for therapy of intracellular infections caused by Salmonella typhimurium or Listeria monocytogenes. In immunosuppressed mice, ABT-719 was more effective than ciprofloxacin against quinolone-sensitive S. aureus, Enterococcus faecalis, and Enterococcus faecium. The pharmacokinetic properties of ABT-719 were consistent with its relative efficacy. The 2-pyridones are potent, orally available antibacterial agents with efficacy against gram-positive and gram-negative bacterial infections in mice.

摘要

2-吡啶酮类是一类新型的口服生物可利用的广谱抗菌剂。这些化合物是强效的细菌DNA回旋酶抑制剂,其与氟喹诺酮类的区别在于环连接处氮原子的位置。ABT-719是一种S异构体,也是一种代表性的2-吡啶酮。在正常小鼠中,口服或皮下注射ABT-719对金黄色葡萄球菌、肺炎链球菌和化脓性链球菌感染的疗效比环丙沙星高4至10倍。ABT-719在治疗由铜绿假单胞菌或大肠杆菌引起的革兰氏阴性菌感染方面与环丙沙星疗效相当。ABT-719的外消旋体和R型对革兰氏阳性菌和革兰氏阴性菌感染产生相似的结果。在治疗由鼠伤寒沙门氏菌或单核细胞增生李斯特氏菌引起的细胞内感染时,ABT-719的50%有效剂量比环丙沙星至少低三倍。在免疫抑制小鼠中,ABT-719对喹诺酮敏感的金黄色葡萄球菌、粪肠球菌和屎肠球菌的疗效比环丙沙星更好。ABT-719的药代动力学特性与其相对疗效一致。2-吡啶酮类是强效的口服可用抗菌剂,对小鼠的革兰氏阳性菌和革兰氏阴性菌感染均有效。

相似文献

1
Efficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections.新型抗菌剂ABT-719及相关2-吡啶酮对实验性细菌感染的疗效。
Antimicrob Agents Chemother. 1995 Apr;39(4):971-5. doi: 10.1128/AAC.39.4.971.
2
Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyelonephritis.
J Antimicrob Chemother. 1996 Oct;38(4):641-53. doi: 10.1093/jac/38.4.641.
3
In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor.新型DNA回旋酶抑制剂ABT-719的体外评估
Antimicrob Agents Chemother. 1995 Apr;39(4):964-70. doi: 10.1128/AAC.39.4.964.
4
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.新型氟喹诺酮类药物ABT-492的体外抗菌效力及抗菌谱
Antimicrob Agents Chemother. 2003 Oct;47(10):3260-9. doi: 10.1128/AAC.47.10.3260-3269.2003.
5
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.A-56619(二氟沙星)和A-56620的体内评估:新型芳基氟喹诺酮类药物
Antimicrob Agents Chemother. 1986 Feb;29(2):201-8. doi: 10.1128/AAC.29.2.201.
6
[The history of the development and changes of quinolone antibacterial agents].[喹诺酮类抗菌药物的发展与变迁史]
Yakushigaku Zasshi. 2003;38(2):161-79.
7
In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.新型氟喹诺酮类药物CFC-222的体外和体内抗菌活性
J Antimicrob Chemother. 1998 Feb;41(2):223-9. doi: 10.1093/jac/41.2.223.
8
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.新型6-氟-8-甲氧基喹诺酮类药物AM-1155的体外和体内抗菌活性
Antimicrob Agents Chemother. 1992 Oct;36(10):2108-17. doi: 10.1128/AAC.36.10.2108.
9
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.新型氟喹诺酮类药物ABT-492体外活性的比较研究
J Antimicrob Chemother. 2004 May;53(5):783-92. doi: 10.1093/jac/dkh180. Epub 2004 Mar 31.
10
In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.一种新型喹诺酮WIN 57273对革兰氏阳性菌具有强效活性,其体外和体内活性研究。
Antimicrob Agents Chemother. 1990 Apr;34(4):568-75. doi: 10.1128/AAC.34.4.568.

引用本文的文献

1
Protective effect of Qnr on agents other than quinolones that target DNA gyrase.Qnr对除喹诺酮类药物外其他靶向DNA促旋酶的药物的保护作用。
Antimicrob Agents Chemother. 2015 Nov;59(11):6689-95. doi: 10.1128/AAC.01292-15. Epub 2015 Aug 3.
2
Efficacies of ABT-773, a new ketolide, against experimental bacterial infections.新型酮内酯ABT-773对实验性细菌感染的疗效。
Antimicrob Agents Chemother. 2001 Sep;45(9):2585-93. doi: 10.1128/AAC.45.9.2585-2593.2001.
3
In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains.ABT-255对药物敏感和耐药结核分枝杆菌菌株的体内疗效。
Antimicrob Agents Chemother. 1998 Oct;42(10):2674-7. doi: 10.1128/AAC.42.10.2674.

本文引用的文献

1
Activity of beta-lactam antibiotics in an animal model against methicillin-resistant Staphylococcus aureus.β-内酰胺类抗生素在动物模型中对耐甲氧西林金黄色葡萄球菌的活性。
J Antimicrob Chemother. 1993 Dec;32(6):919-20. doi: 10.1093/jac/32.6.919.
2
In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.新型氟喹诺酮类药物A-80556的体外和体内评价
Antimicrob Agents Chemother. 1994 May;38(5):1071-8. doi: 10.1128/AAC.38.5.1071.
3
In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis.环丙沙星对从感染性心内膜炎患者分离出的肠球菌的体外和体内活性。
Antimicrob Agents Chemother. 1987 Mar;31(3):430-3. doi: 10.1128/AAC.31.3.430.
4
Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.盐酸替马沙星(A-62254)与两种氟喹诺酮类对照品的抗菌活性比较
Antimicrob Agents Chemother. 1987 Nov;31(11):1768-74. doi: 10.1128/AAC.31.11.1768.
5
beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis.耐氨基糖苷类粪肠球菌所致实验性心内膜炎中β-内酰胺酶的产生
J Infect Dis. 1987 Jun;155(6):1226-32. doi: 10.1093/infdis/155.6.1226.
6
Clinical use of the quinolones.喹诺酮类药物的临床应用。
Lancet. 1987 Dec 5;2(8571):1319-22. doi: 10.1016/s0140-6736(87)91205-0.
7
Quinolones in the treatment of lower respiratory tract infections.喹诺酮类药物在治疗下呼吸道感染中的应用
Rev Infect Dis. 1989 Jul-Aug;11 Suppl 5:S1212-9. doi: 10.1093/clinids/11.supplement_5.s1212.
8
Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis.口服环丙沙星与胃肠外抗生素治疗骨髓炎的比较。
Antimicrob Agents Chemother. 1990 Jan;34(1):40-3. doi: 10.1128/AAC.34.1.40.
9
Activity of temafloxacin against respiratory pathogens.替马沙星对呼吸道病原体的活性。
Antimicrob Agents Chemother. 1991 Mar;35(3):423-9. doi: 10.1128/AAC.35.3.423.
10
Emerging resistance to fluoroquinolones in staphylococci: an alert.葡萄球菌对氟喹诺酮类药物新出现的耐药性:一则警示
Ann Intern Med. 1991 Mar 1;114(5):424-6. doi: 10.7326/0003-4819-114-5-424.